New MRI methods could unlock ARPKD treatment trials

NCT ID NCT07201025

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop better MRI-based tools to measure kidney disease progression in people with Autosomal Recessive Polycystic Kidney Disease (ARPKD), a serious genetic condition with no approved treatments. Researchers will enroll 45 ARPKD patients and 15 healthy volunteers aged 6 and older at two U.S. hospitals. Participants will undergo annual MRI scans and kidney function tests over three years to see if new imaging techniques can reliably track disease changes, which could help speed up future clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive polycystic kidney disease Ciliopathies Polycystic Kidney, Autosomal Recessive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••